Aluminium-Adjuvanted Injectable Suspension Is Stabilized by Adsorption Kinetics, Not Bulk Viscosity

The injectable presentation is the primary registered dosage form for inactivated mink viral enteritis antigen in farmed mink breeding populations. The term API in this biological context denotes the inactivated whole-virus antigen bulk, not a chemical drug substance; downstream formulation steps must preserve immunogenic epitope conformation rather than chemical purity alone. Antigen concentrate supplied as veterinary-grade API is diluted with sterile phosphate-buffered saline to a final pH of 6.8–7.4 and an osmolality of 280–320 mOsm/kg. Aluminium hydroxide gel is added to a final concentration of 0.2–0.5 mg Al³⁺/mL, and adsorption is conducted in a jacketed 316L stainless steel vessel fitted with a bottom-mounted magnetic impeller operating at 120 rpm for 60 min at 2–8 °C. Higher shear rates above 300 rpm have been observed on manufacturing lines to cause aluminium hydroxide aggregation and antigen displacement; rotary homogenisers are therefore avoided in this step. Adsorption efficiency is checked by residual antigen ELISA after 15 min and after 60 min; acceptance is set at no less than 90% antigen bound to the adjuvant phase. Batch-to-batch variance in starting antigen titre requires adjustment of the dilution factor before adjuvant addition, not after, to avoid over-dilution of the adjuvant gel. The final suspension is transferred to a peristaltic filling line fitted with a 20–50 mL stainless steel dosing manifold; fill volume is controlled at 1.0 mL ± 0.05 mL per dose. Sterile filtration of the final suspension is not feasible because the adjuvant particles exceed membrane pore size; the entire formulation is therefore prepared under aseptic conditions in a Grade A zone within a Grade B cleanroom classified under ISO 14644-1:2015. The aseptic process is validated according to ISO 13408-1:2008, including media fills and operator monitoring. Terminal product is filled into Type I borosilicate glass vials closed with chlorobutyl elastomer stoppers and sealed with aluminium flip-off caps.

Regulatory compliance for this presentation is anchored to 9 CFR 113.200 for killed virus vaccines and Ph. Eur. 2.6.1 for sterility. Endotoxin is controlled below 0.5 EU/mL by Ph. Eur. 2.6.14, and sub-visible particulate counts are verified against Ph. Eur. 2.9.19. Aluminium content is verified by inductively coupled plasma–optical emission spectrometry to within ±10% of the label claim. Storage is at 2–8 °C; freezing must be avoided because freeze-thaw cycles can break the antigen-adjuvant bond and release free antigen into the aqueous phase. In-use stability after first needle puncture is limited to 8 h at 15–25 °C.

In regions where cold-chain infrastructure is discontinuous, freeze-dried powder presentations are prepared for distribution channels requiring longer stability outside liquid aqueous storage. The inactivated antigen bulk is formulated with 5.0–10.0% w/v sucrose or trehalose dihydrate, 1.0–2.0% w/v mannitol, and 20 mM L-histidine buffer pH 7.0. The solution is filled at 2–8 °C into 10 mL Type I glass vials with a fill volume of 2.0 mL per vial. Freezing is performed at -40 °C for a minimum of 4 h; the cooling rate is controlled between 0.5–1.0 °C/min. During primary drying, shelf temperature is set to -20 °C and chamber pressure to 10–15 Pa; product temperature is held below the collapse temperature of approximately -25 °C by passive resistance. A conservative primary drying time of 24–36 h is used for 2 mL fill volumes. Secondary drying is conducted at 25 °C for 8–12 h until residual moisture is below 2.0% w/w by Karl Fischer titration according to Ph. Eur. 2.5.12. The lyophilised cake is stored at 2–8 °C under nitrogen headspace; exposure to 25 °C and 60% RH for more than 48 h increases moisture ingress and may reduce antigen recoveries. Reconstitution with 2.0 mL Water for Injections at 25 °C should yield a uniform suspension within 60 s with no visible aggregates; if reconstitution time exceeds 120 s, the batch is quarantined for particle size analysis by dynamic light scattering. Container closure integrity is tested by vacuum decay according to USP <1207>; sterility is verified by Ph. Eur. 2.6.1. Formulation development must account for the freeze-concentrate pH drift associated with phosphate buffers; L-histidine is preferred because phosphate buffer systems can undergo selective crystallization of disodium hydrogen phosphate and lower the freeze-concentrate pH by as much as 3 pH units, denaturing the antigen before sublimation is complete. Published data for this specific antigen in freeze-dried presentation are limited to vaccine master seed studies; each batch must therefore be validated against the parenteral reference product for antigen content and in vivo potency.

What Limits Liquid Oral Solution Stability of an Inactivated Non-Enveloped Virus?

During kit vaccination campaigns where handling stress during injection reduces survival, oral solutions and drenches are investigated as an alternative dosing route. The target liquid must resist gastric pH 1.5–2.5 and enzymatic degradation; the inactivated parvovirus particle is acid-resistant but requires 20 mM citrate-phosphate buffer at pH 6.0–6.5 to prevent aggregation in the formulated product. A mucoadhesive polymer, such as 0.5–1.0% w/v sodium alginate or 1.0–2.0% w/v hydroxypropyl methylcellulose, is included to prolong oropharyngeal and intestinal residence. Osmolality is adjusted with sodium chloride to 280–320 mOsm/kg; excessive tonicity shift above 600 mOsm/kg causes mucosal irritation and reduced acceptance in mink. Preservative compatibility testing is mandatory because benzalkonium chloride at 0.02% w/v can reduce measurable antigen titre by non-specific adsorption, while thiomersal at 0.01% w/v or 2-phenoxyethanol at 0.5% w/v is less disruptive to antigen recovery in forced degradation studies. Fill volume for oral drenches is set at 0.5–1.0 mL; dispensers are calibrated to ±5% of target. Storage is at 2–8 °C in amber high-density polyethylene bottles; freeze-thaw and 25 °C cycling are not permitted. Published immunogenicity data for oral delivery of inactivated mink viral enteritis antigen remain limited; therefore the solution presentation does not replace the injectable product in licensed veterinary immunization schedules without controlled challenge studies.

For solid oral dosage development, direct compression of an inactivated viral antigen presents a thermal and shear boundary distinct from lyophilisate production. The antigen powder is first dry-blended with microcrystalline cellulose at 35–45% w/w, dibasic calcium phosphate anhydrous at 15–20% w/w, croscarmellose sodium at 2.0–5.0% w/w, and magnesium stearate at 0.5–1.0% w/w in a twin-shell blender at 20 rpm for 15–20 min. Blending times above 30 min are avoided because the antigen has a particle size below 50 µm and can segregate. Compression is run on a rotary tablet press with B tooling and 8–12 kN main compression force; pre-compression is held at 2–4 kN to remove entrapped air without generating frictional heat above 40 °C. Tablets are evaluated for hardness 60–90 N, friability below 1.0% w/w per Ph. Eur. 2.9.7, and disintegration below 15 min in water at 37 °C per Ph. Eur. 2.9.1. Because the antigen loses activity at temperatures above 60 °C, wet granulation with aqueous binder is not appropriate unless the inlet air temperature is kept below 35 °C; roller compaction at roll pressure 20–30 kN and gap 1.0–1.5 mm is preferred. Capsule filling uses a dosator-type machine with ±3% weight variation; hydroxypropyl methylcellulose capsules are selected to limit moisture exchange. The terminal tablet or capsule is not a recognised veterinary medicinal product for mink enteritis; stability and efficacy data for this antigen in solid oral forms are limited, and any development batch must be supported by antigen activity testing at each manufacturing step plus in vivo serological response data.

When Feed Premix Granulation Must Avoid High-Shear Denaturation

To avoid high-shear mechanical denaturation, feed premix granules containing the inactivated antigen are manufactured by top-spray fluid-bed granulation rather than high-shear granulation. The carrier is lactose monohydrate or pregelatinised corn starch with a particle size of 60–80 mesh; the binder solution consists of 2.0–5.0% w/v povidone K30 and 0.5–1.0% w/v sodium caseinate in purified water. Granulation is performed in a fluid-bed dryer with inlet air at 45–50 °C, spray rate 8–12 g/min, atomising air pressure 1.5–2.0 bar, and product temperature not exceeding 35 °C. The granules are dried until water activity is below 0.60 and loss on drying is below 5.0% w/w; over-drying below water activity 0.30 increases electrostatic charging and may impair mixing. The concentrated premix is blended with feed at a ratio of 1:100 by weight; homogeneity is confirmed by antigen ELISA across 10 sampling points with a coefficient of variation below 5.0%. The final product is packaged in laminated aluminium pouches with desiccant; oxygen transmission rate of the pouch film is below 0.5 cm³/m²/day at 23 °C. This premix is not a direct substitute for parenteral vaccination; oral antigen exposure through feed may induce variable mucosal immunity depending on mink age, feed intake, and gastric fill. Published data for this configuration is limited, and local regulatory approval should be verified before commercial use.

Before further processing into tablets or capsules, powder and granule intermediates for autogenous vaccine preparation are handled under controlled cleanroom conditions at 35% RH or below. The incoming inactivated antigen bulk is first pre-blended with trehalose dihydrate at 5.0–10.0% w/w and sodium carboxymethylcellulose at 0.5–1.0% w/w to improve flow and prevent caking. The blend is passed through a 0.5 mm stainless steel convective sieve and loaded into double polyethylene-lined drums; each drum is fitted with a desiccant-containing closure. Bulk powder held at 2–8 °C with residual moisture below 3.0% w/w is assigned a retest interval of 12 months; for export shipment to humid climates, insulated thermal blankets and data loggers are used to maintain temperature below 8 °C for up to 72 h. Powder flow properties are checked by angle of repose at 25–35° and Carr’s index at 10–15% before further processing. The granule intermediate may be reconstituted at the farm or compounding facility with purified water at 15–25 °C under gentle agitation for 10–15 min; vigorous shaking is not permitted because air entrapment can oxidise the antigen. The reconstituted suspension should be used within 4 h if held at room temperature; unused product is discarded. This intermediate form is intended only as a starting material for licensed downstream vaccine manufacturing and is not sold as a ready-to-administer vaccine.